The Journal of Immunology, Vol 155, Issue 10 4996-5002, Copyright © 1995 by American Association of Immunologists

ARTICLES

Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody

RF Graziano, PR Tempest, P White, T Keler, Y Deo, H Ghebremariam, K Coleman, LC Pfefferkorn, MW Fanger and PM Guyre
Medarex, Inc., Annandale, NJ 08801, USA.

The murine mAb 22 (M22) binds to the human high affinity receptor for the Fc portion of IgG (Fc gamma RI). This mAb recognizes an epitope on Fc gamma RI that is distinct from the natural ligand (Fc) binding site, and, therefore, can bind to Fc gamma RI in the presence of saturating levels of IgG found in vivo. Fc gamma RI is expressed only on cytotoxic effector cells and it acts as an efficient mediator (trigger molecule) of effector functions. Directing tumor cells or other pathogens to Fc gamma RI utilizing M22 conjugated to an anti-tumor- or to an anti- pathogen-specific mAb may represent an effective method to enhance their removal and destruction under physiologic conditions. Humanization of M22 may improve the therapeutic potential of the mAb since murine mAbs normally elicit a human anti-mouse Ab response. In this report we describe the humanization of M22 by CDR-grafting onto human V region frameworks based on KOL VH and REI V kappa attached to human IgG1 and kappa constant domains. This humanized mAb, H22, displays equivalent binding specificity and affinity as its murine counterpart. In addition, H22 is able to trigger superoxide release from Fc gamma RI-bearing cells, a finding that demonstrates that H22 triggers Fc gamma RI functions. The successful humanization of mAb 22 is an important step in the development of Fc gamma RI-directed immunotherapy.

This article has been cited by other articles:

				M. Schlapschy, M. Fogarasi, H. Gruber, O. Gresch, C. Schafer, Y. Aguib, and A. Skerra Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains Protein Eng. Des. Sel., November 19, 2008; (2008) gzn066v1. [Abstract] [Full Text] [PDF]

				B. Stahnke, T. Thepen, M. Stocker, R. Rosinke, E. Jost, R. Fischer, M. K. Tur, and S. Barth Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes Mol. Cancer Ther., September 1, 2008; 7(9): 2924 - 2932. [Abstract] [Full Text] [PDF]

				D. B. Rawool, C. Bitsaktsis, Y. Li, D. R. Gosselin, Y. Lin, N. V. Kurkure, D. W. Metzger, and E. J. Gosselin Utilization of Fc Receptors as a Mucosal Vaccine Strategy against an Intracellular Bacterium, Francisella tularensis J. Immunol., April 15, 2008; 180(8): 5548 - 5557. [Abstract] [Full Text] [PDF]

				J A G van Roon, J W J Bijlsma, J G J van de Winkel, and F P J G Lafeber Depletion of synovial macrophages in rheumatoid arthritis by an anti-Fc{gamma}RI-calicheamicin immunoconjugate Ann Rheum Dis, June 1, 2005; 64(6): 865 - 870. [Abstract] [Full Text] [PDF]

				J. M. Beekman, J. E. Bakema, J. van der Linden, B. Tops, M. Hinten, M. van Vugt, J. G. J. van de Winkel, and J. H. W. Leusen Modulation of Fc{gamma}RI (CD64) Ligand Binding by Blocking Peptides of Periplakin J. Biol. Chem., August 6, 2004; 279(32): 33875 - 33881. [Abstract] [Full Text] [PDF]

				L. Bevaart, H. H. Van Ojik, A. W. Sun, T. H. Sulahian, J. H. W. Leusen, G. J. Weiner, J. G. J. van de Winkel, and M. J. Van Vugt CpG oligodeoxynucleotides enhance Fc{gamma}RI-mediated cross presentation by dendritic cells Int. Immunol., August 1, 2004; 16(8): 1091 - 1098. [Abstract] [Full Text] [PDF]

				P. Borchmann, R. Schnell, I. Fuss, O. Manzke, T. Davis, L. D. Lewis, D. Behnke, C. Wickenhauser, P. Schiller, V. Diehl, et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma Blood, October 16, 2002; 100(9): 3101 - 3107. [Abstract] [Full Text] [PDF]

				J. Prechl, D. C. Baiu, A. Horvath, and A. Erdei Modeling the presentation of C3d-coated antigen by B lymphocytes: enhancement by CR1/2-BCR co-ligation is selective for the co-ligating antigen Int. Immunol., March 1, 2002; 14(3): 241 - 247. [Abstract] [Full Text] [PDF]

				C. A. Guyre, T. Keler, S. L. Swink, L. A. Vitale, R. F. Graziano, and M. W. Fanger Receptor Modulation by Fc{gamma}RI-Specific Fusion Proteins Is Dependent on Receptor Number and Modified by IgG J. Immunol., December 1, 2001; 167(11): 6303 - 6311. [Abstract] [Full Text] [PDF]

				C. Akewanlop, M. Watanabe, B. Singh, M. Walker, D. W. Kufe, and D. F. Hayes Phagocytosis of Breast Cancer Cells Mediated by Anti-MUC-1 Monoclonal Antibody, DF3, and Its Bispecific Antibody Cancer Res., May 1, 2001; 61(10): 4061 - 4065. [Abstract] [Full Text]

				T. Keler, P. M. Guyre, L. A. Vitale, K. Sundarapandiyan, J. G. J. van de Winkel, Y. M. Deo, and R. F. Graziano Targeting Weak Antigens to CD64 Elicits Potent Humoral Responses in Human CD64 Transgenic Mice J. Immunol., December 15, 2000; 165(12): 6738 - 6742. [Abstract] [Full Text] [PDF]

				T. Keler, P. K. Wallace, L. A. Vitale, C. Russoniello, K. Sundarapandiyan, R. F. Graziano, and Y. M. Deo Differential Effect of Cytokine Treatment on Fc{alpha} Receptor I- and Fc{gamma} Receptor I-Mediated Tumor Cytotoxicity by Monocyte-Derived Macrophages J. Immunol., June 1, 2000; 164(11): 5746 - 5752. [Abstract] [Full Text] [PDF]

				J. Xiang, L. Prasad, L. T.J. Delbaere, and Z. Jia Light-chain framework region residue Tyr71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding Protein Eng. Des. Sel., May 1, 1999; 12(5): 417 - 421. [Abstract] [Full Text] [PDF]